I’m a licensed dermatologist in China and the author of a hypothesis paper published in Medical Hypotheses this year. I’ve already put it to two hair-loss communities, but those are mostly patient populations. I’d rather have it taken apart by people who grade Norwood scales in clinic and read the bone literature. This is a request for criticism, not a presentation of findings.
First, what the hypothesis does not claim
It does not claim that sunlight regrows hair. It does not claim vitamin D deficiency causes AGA. It does not claim baldness is desirable. And it does not dispute the proximate biology — androgen signalling, DHT sensitivity, follicular miniaturization, the regional susceptibility of frontoparietal and vertex follicles. That body of work explains how the phenotype forms, and I take it as given.
My question sits one level down, in Mayr’s sense of proximate versus ultimate causation: once patterned scalp exposure exists, does it produce a secondary systemic consequence that bore on fitness?
The evolutionary problem that motivates it
AGA affects roughly 50% of men by age 50 and up to 80% by 80 in European-descent populations. It carries measurable costs: elevated UV-induced carcinogenesis on the exposed scalp, impaired thermoregulation, and psychosocial penalties that should, in theory, reduce mate-selection fitness. A heritable trait conferring net disadvantage should attenuate over time. It hasn’t.
The standard explanations — sexual signalling of social maturity, antagonistic pleiotropy, genetic hitchhiking with the Xq11-q12 AR/EDA2R locus — are all reasonable, and I want to be clear that weak negative selection on a late-onset trait is a perfectly sufficient null hypothesis. None of them, however, identifies a direct systemic physiological benefit. I’m asking whether one could have coexisted with weak negative selection, not whether it must have.
The proposal
AGA may function as a compensatory “solar window” in carriers of low-efficiency VDR variants.
The FokI polymorphism (rs2228570, C>T) produces a full-length f isoform with roughly 30% lower transcriptional activity than the truncated F isoform, through reduced interaction with TFIIB (Jurutka et al., Mol Endocrinol 2000). The f allele has been associated with lower lumbar spine and femoral neck BMD across multiple populations. If receptor efficiency is genetically fixed, the only remaining lever on downstream signalling is ligand availability.
That’s where the surface-area argument comes in, and it hinges on the denominator. Scalp is 2–3% of total BSA, which sounds negligible. But molecular dating of the clothing louse/head louse divergence places habitual clothing use at roughly 83,000–170,000 years ago — long after functional body hair was lost around 1.2 Mya. In cold-climate clothed humans, routine UVB exposure is restricted to face, hands and sometimes forearms: approximately 5–10% BSA. Against that denominator, advanced AGA (Norwood V–VII) represents a 25–50% relative increase in functional photosynthetic surface.
There’s also a geometric component. Cutaneous UVB irradiance depends heavily on solar zenith angle; below roughly 45°, corresponding to about 10:00–15:00 at mid-latitudes, atmospheric path length is short enough for meaningful UVB transmission. Outside that window, UVB at ground level is negligible regardless of exposed area. During exactly those hours, the vertex of an upright biped is oriented horizontally and receives near-normal incidence, while vertically oriented facial skin and downward-hanging dorsal hands receive the same radiation obliquely, with irradiance reduced by the cosine of the incidence angle. AGA selectively uncovers the one surface that is both temporally and geometrically privileged.
The molecular precondition
VDR-null mice develop complete alopecia despite normal circulating 1,25(OH)2D3, and the alopecia is not rescued by calcium supplementation — the receptor, not the ligand, is doing the work in the follicle (Li et al., PNAS 1997). VDR governs anagen re-entry through interaction with hairless protein: HR binds VDR and represses Wnt targets, and ligand-bound VDR displaces HR. The same Wnt/β-catenin node governs osteoblast differentiation, where β-catenin knockout produces severe trabecular loss.
So VDR, AR and Wnt/β-catenin converge in both follicular and skeletal tissue. I want to state plainly that pathway overlap establishes only that the proposed mechanism could operate. It does not demonstrate that it does, and it is equally consistent with shared developmental origin.
The pharmacological argument, which I think is the most interesting part
Osteoblasts predominantly express 5α-reductase type 1; scalp follicles rely on type 2. Finasteride selectively inhibits type 2, reducing scalp DHT by 60–70% without directly impairing local DHT synthesis in bone. Dutasteride inhibits both isoforms, cutting circulating DHT by 90–95% and blocking osteoblast local DHT production. In Srd5a1-knockout mice, trabecular BMD falls 36% despite unchanged serum androgens.
Yet dutasteride does not produce clinically significant bone loss in humans — most plausibly because elevated substrate testosterone is aromatized to estradiol, which protects bone independently. That’s a compensation story structurally identical to the one I’m proposing: when one bone-protective signal is compromised, another can partially cover for it.
This generates a prediction specific to the model. In FokI ff carriers on dutasteride, three bone-protective signals are simultaneously impaired: AR-mediated local DHT (drug-blocked), VDR-mediated vitamin D signalling (genotype-reduced), and solar-window UVB augmentation (arrested, because the drug halts AGA progression). Those carriers should show the worst BMD trajectory of any genotype–drug combination, while FF homozygotes should show no meaningful difference between finasteride and dutasteride. No alternative framework predicts that three-way interaction.
Why late onset doesn’t automatically kill the argument
AGA typically manifests after peak reproductive age, which is the standard objection. The Grandparent Hypothesis offers one framework: in ancestral hunter-gatherer societies, post-reproductive individuals contributed through provisioning, alloparenting and knowledge transfer, so maintaining skeletal integrity into the sixth and seventh decades would enhance inclusive fitness. Men show steeper age-related cortical loss and higher hip-fracture mortality after 70, while female relatives carrying the same variants had pre-menopausal estrogen protection. I’ll flag that this section of the paper is the most speculative and depends on assumptions I can’t test.
The evidence that cuts against it
- Morton et al. (Rancho Bernardo, J Aging Health 2007): balding men averaged ~5% lower total-body BMD. Reading this as “AGA attenuated an even worse phenotype in variant carriers” is, as I wrote in the paper, an ad hoc accommodation rather than independent support. It becomes testable only in genotype-stratified prospective cohorts.
- Bolland et al. (MJA 2008, n=296): no association between baldness grade and serum 25(OH)D after adjustment for age, season, sunscreen, skin type, outdoor hat use and activity. This is the most direct available test and it is negative. It doesn’t contradict a buffer model, but it does cap the plausible effect size.
- Yap et al. (Nat Commun 2018, n=205,327): a genetic correlation between MPB and increased BMD (rg=0.15), alongside an estimated linear selection gradient of −0.018 per MPB SD. Compatible with my model, but equally compatible with simple pleiotropy — which is the more parsimonious reading and which I can’t currently exclude.
- Li et al. (Int J Cancer 2016, HPFS): frontal plus moderate-to-severe vertex baldness carried an HR of 7.09 for scalp SCC. Any adaptive argument has to clear that cost.
Other confounders I can’t rule out: shared downstream effects of age-related androgen decline; differential sun-seeking behaviour and physical activity in balding men; and the association of AGA with insulin resistance, which independently affects bone.
What would falsify it
- Paired ex vivo UVB irradiation of alopecic vertex and hair-bearing occipital explants from the same individual, quantifying previtamin D3. Within-subject design controls thickness, pigmentation and 7-DHC content. If there’s no per-area advantage, the privileged-window reading collapses and only a trivial surface-area effect survives. This is the single most decisive experiment and, as far as I’m aware, nobody has run it.
- Absence of a genotype-stratified interaction in a well-powered cohort: AGA severity should correlate with femoral neck and lumbar BMD in ff homozygotes but not FF, with 25(OH)D mediating in ff carriers and the effect stronger above 45°N.
- No vertex/frontal-only difference, where the geometric argument predicts one.
- Absence of the genotype × 5ARI × AGA-progression interaction described above.
- Mendelian randomization using independent instruments for AGA susceptibility and VDR function showing the skeletal association is fully explained by passive pleiotropy.
Where I think the real weakness is
A hypothesis positing an effect that is small, cumulative and difficult to detect in modern cohorts drifts toward unfalsifiability. That bothers me more than the negative data does. It’s why I’d rather fix the disconfirming criteria in advance than defend the idea after the fact. If the predicted interactions are absent in adequately powered studies, the adaptive component should be dropped.
Prior discussion
I spent about a month answering objections in two hair-loss communities. If you’d like to see what has already been argued rather than re-litigate it:
The recurring objections across both were: women and children need UVB too; AGA manifests after peak reproduction; the baldest populations live at low latitudes; and the effect is too small to separate from geography and lifestyle. I’ve answered all four there, so I’d be more interested here in mechanistic objections that haven’t come up yet.
Questions for this sub
- Is there a tissue-level reason to expect alopecic vertex epidermis to differ in 7-DHC content or previtamin D3 yield beyond simple shaft attenuation and interfollicular shadowing? Does anyone know of explant work bearing on this?
- For those following AGA genetics closely: is the Yap pleiotropy result sufficient on its own to make an adaptive account unnecessary?
- Does any biobank hold concurrent Norwood grading, VDR genotype and DXA, such that the stratified test could be run without new recruitment?
- For the hair transplant surgeons here: is there a feasible route to obtaining paired vertex and occipital explants under an existing surgical protocol?
Full text: Zhang T. The solar window hypothesis: androgenetic alopecia as an evolutionary adaptation to maintain bone mineral density in vitamin D receptor low-efficiency variants. Med Hypotheses. 2026;212:112005. doi:10.1016/j.mehy.2026.112005
COI: Sole author of the paper discussed. No funding. No commercial interest in AGA treatment.
